Halyard Health Company Profile (NYSE:HYH)

About Halyard Health (NYSE:HYH)

Halyard Health logoHalyard Health, Inc. is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections. The Company address healthcare needs, such as reducing the use of opioids, while helping patients move from surgery to recovery. The Medical Devices segment's products include post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems and enteral feeding tubes. The S&IP segment includes product offerings, such as sterilization wrap, surgical drapes and gowns, facial protection, protective apparel and medical exam gloves.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: N/A
  • Symbol: NYSE:HYH
  • CUSIP: N/A
  • Web: www.halyardhealth.com
Capitalization:
  • Market Cap: $2.05932 billion
  • Outstanding Shares: 46,700,000
Average Prices:
  • 50 Day Moving Avg: $45.23
  • 200 Day Moving Avg: $40.71
  • 52 Week Range: $31.59 - $46.63
P/E:
  • Trailing P/E Ratio: 42.32
  • Foreward P/E Ratio: 21.06
  • P/E Growth: 4.28
Sales & Book Value:
  • Annual Revenue: $1.6 billion
  • Price / Sales: 1.28
  • Book Value: $24.77 per share
  • Price / Book: 1.78
Profitability:
  • EBITDA: $182 million
  • Net Margins: 3.06%
  • Return on Equity: 8.29%
  • Return on Assets: 4.44%
Debt:
  • Debt-to-Equity Ratio: 0.50%
  • Current Ratio: 2.03%
  • Quick Ratio: 1.11%
Misc:
  • Average Volume: 336,538 shs.
  • Beta: 1.75
  • Short Ratio: 11.18
 

Frequently Asked Questions for Halyard Health (NYSE:HYH)

What is Halyard Health's stock symbol?

Halyard Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "HYH."

How were Halyard Health's earnings last quarter?

Halyard Health, Inc. (NYSE:HYH) posted its quarterly earnings results on Wednesday, August, 2nd. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.37 by $0.14. The business earned $399.20 million during the quarter, compared to analysts' expectations of $399.16 million. Halyard Health had a return on equity of 8.29% and a net margin of 3.06%. The company's quarterly revenue was down .2% compared to the same quarter last year. During the same period last year, the firm earned $0.45 EPS. View Halyard Health's Earnings History.

When will Halyard Health make its next earnings announcement?

Halyard Health is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Halyard Health.

What guidance has Halyard Health issued on next quarter's earnings?

Halyard Health issued an update on its FY18 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of $1.85-2.05 for the period, compared to the Thomson Reuters consensus estimate of $2.04.

Where is Halyard Health's stock going? Where will Halyard Health's stock price be in 2017?

5 brokers have issued 1 year target prices for Halyard Health's stock. Their forecasts range from $38.00 to $45.00. On average, they expect Halyard Health's share price to reach $41.67 in the next year. View Analyst Ratings for Halyard Health.

What are analysts saying about Halyard Health stock?

Here are some recent quotes from research analysts about Halyard Health stock:

  • 1. According to Zacks Investment Research, "Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. " (10/19/2017)
  • 2. Stifel Nicolaus analysts commented, "HYH closed 2016 with its fourth consecutive quarter of sales and EPS upside relative to both Consensus and management guidance. After a more difficult than expected first-year (2015) post-spin, in 2016, the company's transformation took clearer shape and was highlighted by: accretive M&A, a positive mix shift to the more profitable Medical Device franchise (38% of sales; 64% of operating profit), successful re-negotiations of material GPO contracts, significant organic cost-savings and stepped-up investments, all with significantly improved cash flow generation ($100M+ guide vs. $160M actual). We continue to believe HYH has further price appreciation potential ahead as '2016-like' thematic drivers continue playing out over the next 12-24 months. Still, we acknowledge that HYH shares (+56% TTM vs. S&P500: +23%) trading at 20x 2018E EPS (vs. large cap ~18x) could "pause" here as the stock absorbs the recent out-performance and the next wave of potentially positive catalysts becomes more visible. Yet to be realized sales, margin, and EPS-enhancing catalysts could include: IT cost savings, better S&IP pricing, more normal nitrile pricing and most important, further accretive M&A opportunities. Company-specific 2017 headwinds could include: more intense commodity price inflation, stepped up On-Q competition, and still uncertain macro tax-related legislation. For us, the bottom line is that HYH remains a positive long-term transformation story that is still in 'early innings' with significant opportunity both organically and through acquisitions to leverage earnings. We rate HYH Buy and raise our TP to $45 (from $38)." (2/28/2017)

Who are some of Halyard Health's key competitors?

Who are Halyard Health's key executives?

Halyard Health's management team includes the folowing people:

  • Ronald W. Dollens, Chairman of the Board
  • Joseph F. Woody, Chief Executive Officer, Director
  • Steven E. Voskuil, Chief Financial Officer, Senior Vice President
  • Christopher M. Lowery, Chief Operating Officer, Senior Vice President
  • Rhonda D. Gibby, Chief Human Resource Officer, Senior Vice President
  • John W. Wesley, Senior Vice President, General Counsel
  • Christopher G. Isenberg, Senior Vice President - Global Supply Chain and Procurement
  • Warren J. Machan, Senior Vice President - Business Strategy
  • Gary D. Blackford, Independent Director
  • John P. Byrnes, Independent Director

Who owns Halyard Health stock?

Halyard Health's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Treasurer State of Michigan (0.04%), Narwhal Capital Management (0.03%), Alpha Windward LLC (0.02%) and Quotient Investors LLC (0.01%). View Institutional Ownership Trends for Halyard Health.

Who sold Halyard Health stock? Who is selling Halyard Health stock?

Halyard Health's stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan and Alpha Windward LLC. View Insider Buying and Selling for Halyard Health.

Who bought Halyard Health stock? Who is buying Halyard Health stock?

Halyard Health's stock was bought by a variety of institutional investors in the last quarter, including Narwhal Capital Management and Quotient Investors LLC. View Insider Buying and Selling for Halyard Health.

How do I buy Halyard Health stock?

Shares of Halyard Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Halyard Health's stock price today?

One share of Halyard Health stock can currently be purchased for approximately $44.01.


MarketBeat Community Rating for Halyard Health (NYSE HYH)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  268
MarketBeat's community ratings are surveys of what our community members think about Halyard Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Halyard Health (NYSE:HYH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $41.67 (5.32% downside)
Consensus Price Target History for Halyard Health (NYSE:HYH)
Price Target History for Halyard Health (NYSE:HYH)
Analysts' Ratings History for Halyard Health (NYSE:HYH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017KeyCorpReiterated RatingHoldN/AView Rating Details
9/21/2017Stifel NicolausReiterated RatingBuy$45.00LowView Rating Details
8/3/2017Deutsche Bank AGBoost Price TargetBuy$35.00 -> $42.00MediumView Rating Details
8/3/2017StephensUpgradeEqual Weight -> OverweightMediumView Rating Details
1/6/2017JMP SecuritiesDowngradeOutperform -> Market Perform$38.00N/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Halyard Health (NYSE:HYH)
Earnings by Quarter for Halyard Health (NYSE:HYH)
Earnings History by Quarter for Halyard Health (NYSE HYH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017$0.47N/AView Earnings Details
8/2/2017Q2 2017$0.37$0.51$399.16 million$399.20 millionViewListenView Earnings Details
5/2/2017Q1 2017$0.43$0.48$391.56 million$395.60 millionViewListenView Earnings Details
2/27/2017Q416$0.44$0.50$401.72 million$410.00 millionViewListenView Earnings Details
11/2/2016Q316$0.39$0.48$387.64 million$398.00 millionViewN/AView Earnings Details
8/3/2016Q216$0.36$0.45$383.08 million$400.00 millionViewN/AView Earnings Details
5/4/2016Q116$0.34$0.53$369.80 million$385.00 millionViewN/AView Earnings Details
2/29/2016Q415$0.50$0.57$401.96 million$401.40 millionViewListenView Earnings Details
11/3/2015Q315$0.47$0.52$388.00 million$390.00 millionViewN/AView Earnings Details
8/4/2015Q215$0.53$0.52$401.70 million$389.30 millionViewN/AView Earnings Details
5/4/2015Q1 2015$0.64$0.51$390.00 million$394.00 millionViewN/AView Earnings Details
3/4/2015Q4$0.75$1.59$425.10 million$439.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Halyard Health (NYSE:HYH)
2017 EPS Consensus Estimate: $1.80
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.44$0.44$0.44
Q2 20171$0.40$0.40$0.40
Q3 20171$0.45$0.45$0.45
Q4 20171$0.51$0.51$0.51
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Halyard Health (NYSE:HYH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Halyard Health (NYSE:HYH)
Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 91.02%
Insider Trades by Quarter for Halyard Health (NYSE:HYH)
Institutional Ownership by Quarter for Halyard Health (NYSE:HYH)
Insider Trades by Quarter for Halyard Health (NYSE:HYH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/4/2015Robert E AbernathyCEOBuy10,000$31.06$310,600.00View SEC Filing  
9/1/2015Steven E VoskuilCFOBuy1,000$30.00$30,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Halyard Health (NYSE:HYH)
Latest Headlines for Halyard Health (NYSE:HYH)
Source:
Loading headlines, please wait.

Social

Chart

Halyard Health (HYH) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.